Acute Myeloid Leukemia and Myelodysplastic Syndrome
Oncology
2
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Monoclonal Antibody
1100%
+ 1 programs with unclassified modality
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Qilu PharmaceuticalQLF32101
Bristol Myers SquibbNivolumab
Clinical Trials (2)
Total enrollment: 8 patients across 2 trials
A Study of QLF32101 in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome
Start: Feb 2023Est. completion: Dec 2024
Phase 1Unknown
Single Agent and Combined Inhibition After Allogeneic Stem Cell Transplant
Start: Mar 2019Est. completion: Dec 20238 patients
Phase 1Terminated
Related Jobs in Oncology
Senior Research Associate, Immuno-Oncology
SystImmune
4h ago
$60K - $85K/yr
Research Associate I/II, Immuno-Oncology
SystImmune
4h ago
Office Administrator
SystImmune
4h ago
$60K - $80K/yr
Scientist/Sr Scientist
TwoStep Therapeutics
San Carlos
4h ago
Senior Medical Project Manager (m/f/d)
Mindpeak
Hamburg
4h ago
Working Student Active Sourcing Support (m/f/d)
Mindpeak
Hamburg
4h ago
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
Monoclonal Antibody is the dominant modality (100% of programs)
2 companies competing in this space